JP2021527098A5 - - Google Patents

Info

Publication number
JP2021527098A5
JP2021527098A5 JP2020569169A JP2020569169A JP2021527098A5 JP 2021527098 A5 JP2021527098 A5 JP 2021527098A5 JP 2020569169 A JP2020569169 A JP 2020569169A JP 2020569169 A JP2020569169 A JP 2020569169A JP 2021527098 A5 JP2021527098 A5 JP 2021527098A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
cells
cancer
alkyls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020569169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527098A (ja
JP7365059B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036581 external-priority patent/WO2019241271A1/en
Publication of JP2021527098A publication Critical patent/JP2021527098A/ja
Publication of JP2021527098A5 publication Critical patent/JP2021527098A5/ja
Application granted granted Critical
Publication of JP7365059B2 publication Critical patent/JP7365059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020569169A 2018-06-13 2019-06-11 縮合チオフェン化合物 Active JP7365059B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684495P 2018-06-13 2018-06-13
US62/684,495 2018-06-13
PCT/US2019/036581 WO2019241271A1 (en) 2018-06-13 2019-06-11 Fused thiophene compounds

Publications (3)

Publication Number Publication Date
JP2021527098A JP2021527098A (ja) 2021-10-11
JP2021527098A5 true JP2021527098A5 (https=) 2022-06-10
JP7365059B2 JP7365059B2 (ja) 2023-10-19

Family

ID=67263033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569169A Active JP7365059B2 (ja) 2018-06-13 2019-06-11 縮合チオフェン化合物

Country Status (8)

Country Link
US (2) US11191769B2 (https=)
EP (1) EP3807283A1 (https=)
JP (1) JP7365059B2 (https=)
CN (1) CN112601751B (https=)
AU (1) AU2019284605A1 (https=)
CA (1) CA3101335C (https=)
TW (1) TWI826463B (https=)
WO (1) WO2019241271A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブリストル-マイヤーズ スクイブ カンパニー Heliosタンパク質の阻害剤として有用な化合物
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
JP2023545274A (ja) * 2020-10-07 2023-10-27 クルゲン(シャンハイ),インク. 癌を処置する化合物および方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN117203196A (zh) 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
EP4320112B1 (en) 2021-04-06 2025-05-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN119371398A (zh) * 2023-07-25 2025-01-28 安道麦阿甘有限公司 用于制备噻吩酮的新路线
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
AU2015305449B2 (en) * 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
SG11201708303XA (en) * 2015-05-22 2017-11-29 Biotheryx Inc Compounds targeting proteins, compositions, methods, and uses thereof
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Similar Documents

Publication Publication Date Title
JP2021527098A5 (https=)
AU2019414550B2 (en) FAK inhibitor and drug combination thereof
RU2018104092A (ru) Бициклические лактамы и способы их применения
CN110573501A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2015535851A5 (https=)
RU2012151012A (ru) Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
AR122010A1 (es) Compuestos heterocíclicos como receptores desencadenantes expresados en agonistas de células mieloides 2 y métodos de uso
JP2013525458A5 (https=)
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
JP2016513660A5 (https=)
FI3810602T3 (fi) Yhdisteitä
CA3051645A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
JP2021516237A5 (https=)
CA2579915A1 (en) Indole derivatives and their use as inhibitors of p53-mdm2 interaction
JP2017511357A5 (https=)
JP2019535720A5 (https=)
JP2022507267A5 (https=)
JP2015534574A5 (https=)
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
JP2018507877A5 (https=)
JP2017509586A5 (https=)
JP2009543771A5 (https=)
RU2017139771A (ru) Бициклические соединения
JP2025502377A5 (https=)